ADP receptors-target for developing antithrombotic agents

Current Pharmaceutical Design

Volumn 9, Issue 28, 2003, Pages 2303-2316

  Kunapuli, Satya P ^a   Ding, Zhongren ^a   Dorsam, Robert T ^a   Kim, Soochong ^a   Murugappan, Swaminathan ^a   Quinton, Todd M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADP receptor; P2X1 receptor; P2Y1 receptor; P2Y12 receptor; Platelet aggregation; Platelets

Indexed keywords

2 CHLORO N6 METHYL (N) METHANOCARBA 2' DEOXYADENOSINE 3',5' DIPHOSPHATE; 2' DEOXY 6 N METHYLADENOSINE 3',5' BISPHOSPHATE; 6 N (2 METHYLTHIOETHYL) 2 (3,3,3 TRIFLUOROPROPYLTHIO)ADENOSINE PHOSPHATE; ACETYLSALICYLIC ACID; ADENINE NUCLEOTIDE; ADENOSINE 3' PHOSPHATE 5' PHOSPHOSULFATE; ADENOSINE DIPHOSPHATE; ADENYLATE CYCLASE; ANTACID AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AR C 66096; AR C 66906; AR C 67085; ATORVASTATIN; CANGRELOR; CLOPIDOGREL; DIGOXIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; MRS 2279; NAPROXEN; PHOSPHATIDYLINOSITOL 3 KINASE; PRASUGREL; PURINE P2X RECEPTOR; PURINE P2Y RECEPTOR; R 99224; RECEPTOR BLOCKING AGENT; THEOPHYLLINE; THROMBOXANE A2; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; FIBRINOLYTIC AGENT; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PURINE P2 RECEPTOR; PURINE P2X1 RECEPTOR; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; PYRIDINE DERIVATIVE; THIENOPYRIDINE;

ARTERY DISEASE; ARTHRITIS; BLEEDING TENDENCY; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ECCHYMOSIS; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CLEARANCE; MALE; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PRURITUS; RASH; RECEPTOR AFFINITY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; URTICARIA; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY;

ANIMALS; CLINICAL TRIALS; FIBRINOLYTIC AGENTS; HUMANS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; PYRIDINES; RECEPTORS, PURINERGIC P2;

EID: 0141989954     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033453947     Document Type: Review

References (135)

1. Abbracchio MP, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Miras-Portugal MT, et al. Characterization of the UDP-glucose receptor (re-named here the P2Y(14) receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci 2003; 24: 52-5.
2. Atkinson BT, Stafford MJ, Pears CJ, Watson SP. Signalling events underlying platelet aggregation induced by the glycoprotein VI agonist convulxin. Eur J Biochem 2001; 268: 5242-8.
3. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-7.
4. Bennett JS. Platelet-fibrinogen interactions. Ann N Y Acad Sci 2001; 936: 340-54.
5. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98: 1597-603.
6. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, Investigators FT. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624-9.
7. Boneu B, Destelle G. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb Haemost 1996; 76: 939-43.
8. Boyer JL, Adams M, Ravi RG, Jacobson KA, Harden TK. 2-Chloro N(6)-methyl-(N)-methanocarba-2′-deoxyadenosine-3′, 5′-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol 2002; 135: 2004-10.
9. Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2′-deoxyadenosine 3′, 5′-bisphosphate. Br J Pharmacol 1998; 124: 1-3.
10. Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol 1996; 50: 1323-9.
11. Briguori C, Manganelli F, Picardi M, Villari B, Ricciardelli B. Thrombocytopenia and purpura-like lesions associated with clopidogrel. Ital Heart J 2001; 2: 935-7.
12. Brown SG, King, BF, Kim YC, Jang SY, Burnstock G, Jacobson KA. Activity of novel adenine nucleotide derivatives as agonists and antagonists at recombinant rat P2X receptors. Drug Devel Res. 2000; 49: 253-59.
13. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 2002; 106: 1622-6.
14. Caplain H, Cariou R. Long-term activity of clopidogrel: a three-month appraisal in healthy volunteers. Semin Thromb Hemost 1999; 25 Suppl 2: 21-4.
15. Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999, 25 Suppl 2: 25-8.
16. Caplain H, Thebault JJ, Necciari J. Clopidogrel does not affect the pharmacokinetics of theophylline. Semin Thromb Hemost 1999; 25 Suppl 2: 65-8.
17. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet aggregation characterized by severe impairment of platelet responses to adenosine 5′-diphosphate. Blood 1992; 80: 2787-96.
18. Chattaraj SC. Cangrelor AstraZeneca. Curr Opin Investig Drugs 2001; 2: 250-5.
19. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med 1998; 3: 257-60.
20. Committee CS. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-39.
21. Coukell AJ, Markham A. Clopidogrel. Drugs 1997; 54: 745-50; discussion 51.
22. Dangelmaier C, Jin J, Daniel JL, Smith JB, Kunapuli SP. The P2Y1 receptor mediates ADP-induced p38 kinase-activating factor generation in human platelets. Eur J Biochem 2000; 267: 2283-9.
23. Dangelmaier C, Jin J, Smith JB, Kunapuli SP. Potentiation of thromboxane A2-induced platelet secretion by Gi signaling through the phosphoinositide-3 kinase pathway. Thromb Haemost 2001; 85: 341-8.
24. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 2024-9.
25. Daniel JL, Dangelmaier C, Jin J, Kim YB, Kunapuli SP. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemost 1999; 82: 1322-6.
26. Davie AP, Love MP. CAPRIE trial. Lancet 1997; 349: 355; discussion 56.
27. Denninger MH, Necciari J, Serre-Lacroix E, Sissmann J. Clopidogrel antiplatelet activity is independent of age and presence of atherosclerosis. Semin Thromb Hemost 1999; 25: 41-5.
28. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 2003; 101: 3908-14.
29. Dippel DW. The results of CAPRIE, IST and CAST. Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events. International Stroke Trial. Chinese Acute Stroke Trial. Thromb Res 1998; 92: S13-6.
30. Donnan GA, Davis SM. Aspirin therapy should be first line: probably, but watch this space. Stroke 2002; 33: 2139-40.
31. Dorr G, Schmidt G, Grafe M, Regitz-Zagrosek V, Fleck E. Effects of combined therapy with clopidogrel and acetylsalicylic acid on platelet glycoprotein expression and aggregation. J Cardiovasc Pharmacol 2002; 39: 523-32.
32. Eckly A, Gendrault JL, Hechler B, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2YT receptors in the morphological changes of platelet aggregation. Thromb Haemost 2001; 85: 694-701.
33. Evens AM, Kwaan HC, Kaufman DB, Bennett CL. TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology. Transplantation 2002; 74: 885-7.
34. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199-202.
35. Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, et al. P2y(1)-receptors in human platelets which are pharmacologically distinct from P2y(ADP)-receptors. Br J Pharmacol 1998; 124: 157-64.
36. Fareed J, Messmore, H. Preface: Clopidogrel. Semin Thromb Hemost 1999; 25, Suppl. 2: i-ii.
37. Fisher AA, Le Couteur DG. Intracerebral hemorrhage following possible interaction between celecoxib and clopidogrel. Ann Pharmacother 2001; 35: 1567-9.
38. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-8.
39. Garg A, Radvan J, Hopkinson N. Clopidogrel associated with acute arthritis. Br Med J 2000; 320: 483.
40. Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 1998, 351: 235-46.
41. Gent M. The CAPRIE trial: culmination of the preregistration program for clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Clopidogrel versus aspirin in patients at risk of ischaemic events. Semin Thromb Hemost 1999; 25: 1-2.
42. Goto S, Tamura N, Eto K, Ikeda Y, Handa S. Functional significance of adenosine 5′-diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002; 105: 2531-6.
43. Green MJ, Iveson M, Crook R, Burrows N, Gough AK. Careless talk may cost lives in attributing adverse events to ADP receptor antagonists. Br Med J 2002; 324: 1039.
44. Hacke W. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002; 13: 22-6.
45. Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, et al. The P2y(1) receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92: 152-59.
46. Hechler B, Vigne P, Leon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol 1998; 53: 727-33.
47. Hirsch E, Bosco O, Tropel P, Laffargue M, Calvez R, Altruda F, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001, 15: 2019-21.
48. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-7.
49. Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J Pharmacol Exp Ther 2000; 295: 492-9.
50. 2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci 1995; 16: 179-81.
51. Humphries RG, Tomlinson W, Clegg JA, Ingall AH, Kindon ND, Leff P. Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br J Pharmacol 1995; 115: 1110-6.
52. Humphries RG, Tomlinson W, Ingall AH, Cage PA, Leff P. FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br J Pharmacol 1994: 113: 1057-63.
53. Investigators CT. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
54. Jacobsen W, Kuhn B, Soldner A, Kirchner G, Sewing KF, Kollman PA, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000; 28: 1369-78.
55. Jantzen H-M, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds E, et al. Evidence for two distinct G protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 1999; 81: 111-17.
56. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 2001; 108: 477-83.
57. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030-4.
58. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95: 8070-4.
59. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002; 99: 193-8.
60. Jung SM, Moroi M. Platelet collagen receptor integrin alpha2beta1 activation involves differential participation of ADP-receptor subtypes P2Y1 and P2Y12 but not intracellular calcium change. Eur J Biochem 2001; 268: 3513-22.
61. Kauffenstein G, Bergmeier W, Eckly A, Ohlmann P, Leon C, Cazenave JP, et al. The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin - a phosphoinositide 3- kinase-dependent mechanism. FEBS Lett 2001; 505: 281-90.
62. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. J Am Coll Cardiol 2002; 40: 218-9.
63. Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, et al. Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem 2002; 45: 208-18.
64. King SB, 3rd. Optimizing antiplatelet therapy in coronary interventions. Clin Cardiol 2000; 23 Suppl 6: VI-8-13.
65. Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, Mortensen RM, et al. Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 2003; 101: 1409-15.
66. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
67. Leon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin- dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001; 103: 718-23.
68. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104: 1731-7.
69. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-71.
70. MacKenzie AB, Mahaut-Smith MP, Sage SO. Activation of receptor-operated cation channels via P2X1 not P2T purinoceptors in human platelets. J Biol Chem 1996; 271: 2879-81.
71. Mahaut-Smith MP, Ennion SJ, Rolf MG, Evans RJ. ADP is not an agonist at P2X(1) receptors: evidence for separate receptors stimulated by ATP and ADP on human platelets. Br J Pharmacol 2000; 131: 108-14.
72. McEwen J, Strauch G, Perles P, Pritchard G, Moreland TE, Necciari J, et al. Clopidogrel bioavailability: absence of influence of food or antacids. Semin Thromb Hemost 1999; 25: 47-50.
73. Mitka M. Results of CURE trial for acute coronary syndrome. JAMA 2001; 285: 1828-9.
74. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, et al. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 2000; 403: 86-9.
75. Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem 2000; 43: 829-42.
76. Nassim MA, Gardner JJ, Wilkinson D, Corfield JE, Wyld PJ. The short-acting P2T-purinoceptor antagonist, FPL 67085, reliably, reversibly and safely inhibits ADP-induced platelet aggregation ex vivo in man. Br J Clin Pharmacol 1995; 39: 98P.
77. Nikhil JY, Radhakrishnan S, Paradiso-Hardy FL, Cohen EA. Clopidogrel in interventional cardiology: questions answered and questions remaining. Can J Cardiol 2002; 18: 739-48
78. Ohlmann P, Eckly A, Freund M, Cazenave JP, Offermanns S, Gachet C. ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood 2000; 96: 2134-9.
79. Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, Cazenave JP, et al. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312: 775-9.
80. Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, et al. Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 2003; 101: 3969-76.
81. Oury C, Toth-Zsamboki E, Thys C, Tytgat J, Vermylen J, Hoylaerts MF. The ATP-gated P2X1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemost 2001; 86: 1264-71.
82. Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF. P2X(1)-mediated activation of extracellular signal-regulated kinase 2 contributes to platelet secretion and aggregation induced by collagen. Blood 2002; 100: 2499-505.
83. Paradiso-Hardy FL, Papastergiou J, Lanctot KL, Cohen EA. Thrombotic thrombocytopenic purpura associated with clopidogrel: further evaluation. Can J Cardiol 2002; 18: 771-3.
84. Paul BZ, Jin J, Kunapuli SP. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 1999; 274: 29108-14.
85. Paul BZS, Vilaire G, Kunapuli SP, Bennett JS. Concurrent signaling from Galphaq- and Galphai-coupled pathways is essential for agonist-induced alphaVbeta3 activation on human platelets. J Thromb Haemost 2003; in press:
86. Payne DA, Hayes PD, Jones CI, Belham P, Naylor AR, Goodall AH. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg 2002; 35: 1204-9.
87. Peeters PA, Crijns HJ, Tamminga WJ, Jonkman JH, Dickinson JP, Necciari J. Clopidogrel, a novel antiplatelet agent, and digoxin: absence of pharmacodynamic and pharmacokinetic interaction. Semin Thromb Hemost 1999; 25 Suppl 2: 51-4.
88. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, et al. Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 2002; 30: 1288-95.
89. Pierce CH, Houle JM, Dickinson JP, Kindermans M, Serre-Lacroix E, Kieffer G, et al. Clopidogrel and drug metabolism: absence of effect on hepatic enzymes in healthy volunteers. Semin Thromb Hemost 1999; 25: 35-9.
90. Quinton TM, Kim S, Dangelmaier C, Dorsam RT, Jin J, Daniel JL, et al. Protein kinase C- and calcium-regulated pathways independently synergize with Gi pathways in agonist-induced fibrinogen receptor activation. Biochem J 2002; 368: 535-43.
91. Quinton TM, Ozdener F, Dangelmaier C, Daniel JL, Kunapuli SP. Glycoprotein VI-mediated platelet fibrinogen receptor activation occurs through calcium-sensitive and PKC-sensitive pathways without a requirement for secreted ADP. Blood 2002; 99: 3228-34.
92. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413-92.
93. Reichenberger F, Wirtz H, Paschke R. Clopidogrel and side effects. Cardiology 2001; 96: 51-2.
94. Remijn JA, Wu YP, Jeninga EH, van Willigen G, de Groot PG, et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686-91.
95. Rodriguez A, Ambrose JA. Do we require a cure for "stentmania"? J Am Coll Cardiol 1996; 28: 827-9.
96. Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha, beta-methylene ATP. Thromb Haemost 2001; 85: 303-8.
97. Rolf MG, Mahaut-Smith MP. Effects of enhanced P2X1 receptor Ca2+ influx on functional responses in human platelets. Thromb Haemost 2002; 88: 495-502.
98. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999; 25 Suppl 2: 15-9.
99. Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994; 72: 313-7.
100. Savi P, Labouret C, Delesque N, Guette F, Lupker J, Herbert JM. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-83.
101. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000; 84: 891-6.
102. Scase TJ, Heath MF, Allen JM, Sage SO, Evans RJ. Identification of a P2X1 purinoceptor expressed on human platelets. Biochem Biophys Res Commun 1998; 242: 525-8.
103. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
104. Shaknovich A. Complications of coronary stenting. Coron Artery Dis 1994; 5: 583-9.
105. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998; 129: 394-405.
106. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002; 88: 488-94.
107. Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 2001, 12: 443-7.
108. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001; 85: 401-7.
109. Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 2000; 110: 925-34.
110. Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets 2002; 13: 407-13.
111. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol 2000; 129: 1439-46.
112. Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K, Koike H. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol 2001; 132: 47-54.
113. Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998; 273: 11544-7.
114. Takano S, Kimura J, Matsuoka I, Ono T. No requirement of P2X1 purinoceptors for platelet aggregation. Eur J Pharmacol 1999; 372: 305-9.
115. Takasaki J, Kamohara M, Saito T, Matsumoto M, Matsumoto S, Ohishi T, et al. Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Mol Pharmacol 2001; 60: 432-9.
116. Thebault JJ, Kieffer G, Lowe GD, Nimmo WS, Cariou R. Repeated-dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999; 25 Suppl 2: 9-14.
117. Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340-5.
118. Uthman IW, Dakik HA, Salti I, Haidar R. Authors' refute careless talk about ADP receptor antagonists. Br Med J 2002; 325: 1036.
119. van Hecken A, Depre M, Wynants K, Vanbilloen H, Verbruggen A, Arnout J, et al. Effect of clopidogrel on naproxen-induced gastrointestinal blood loss in healthy volunteers. Drug Metabol Drug Interact 1998; 14: 193-205.
120. Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 1500-4.
121. Vial C, Rolf MG, Mahaut-Smith MP, Evans RJ. A study of P2X1 receptor function in murine megakaryocytes and human platelets reveals synergy with P2Y receptors. Br J Pharmacol 2002; 135: 363-72.
122. Vigne P, Hechler B, Gachet C, Breittmayer JP, Frelin C. Benzoyl ATP is an antagonist of rat and human P2Y1 receptors and of platelet aggregation. Biochem Biophys Res Common 1999; 256: 94-7.
123. Wagner WR, Hubbell JA. ADP receptor antagonists and converting enzyme systems reduce platelet deposition onto collagen. Thromb Haemost 1992; 67: 461-67.
124. Weaver WD, Harrington RA, Grines CL, Keeley EC, Kereiakes DJ, Bittl JA, et al. Intravenous AR-C69931MX, a Novel P2T Platelet receptor Antagonist, in Patients Undergoing Percutaneous Coronary Interventions-Preliminary results from a Placebo or Active Controlled Trial. J Amer Coll Cardiol 1999; 35: 36.
125. Webb TE, Barnard EA. Molecular biology of P2Y receptors expressed in the nervous system. Prog Brain Res 1999; 120: 23-31.
126. Weksler BB. Antiplatelet agents in stroke prevention. combination therapy: present and future. Cerebrovasc Dis 2000; 10 Suppl 5: 41-8.
127. Yang J, Wu J, Jiang H, Mortensen R, Austin S, Manning DR, et al Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors. J Biol Chem 2002; 277: 46035-42.
128. Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, et al. ADP is the cognate ligand for the orphan G-protein coupled receptor SP1999. J Biol Chem 2001; 276: 8608-15.
129. Zhang FL, Luo L, Gustafson E, Palmer K, Qiao X, Fan X, et al. P2Y(13): Identification and Characterization of a Novel Galphai-Coupled ADP Receptor from Human and Mouse. J Pharmacol Exp Ther 2002; 301: 705-13.
130. Zhao L, Bath P, Heptinstall S. Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro. Br J Pharmacol 2001; 134: 353-8.
131. Dorsam RT, Kim S, Jin J, Kunapuli SP. Coordinated signaling through both G12/13 and Gi pathways is sufficient to activate GPIIb/IIIa in human platelets. J Biol Chem 2002; 277: 47588-95.
132. Nieswandt B, Schulte V, Zywietz A, Gratacap MP, Offermanns S. Costimulation of Gi and G12/G13-mediated signaling pathways induces integrin alpha IIbeta 3 activation in platelets. J Biol Chem 2002; 277: 39493-8.
133. Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, et al.Structure-activity relationships of suramin and pyridoxal-5′-phosphate derivatives as P2 receptor antagonists. Curr Pharm Design 2002; 8(26): 2371-99.
134. Moro S, Jacobson KA. Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharm Design 2002; 8(26): 2401-13.
135. Muller CE. P2-pyrimidinergic receptors and their ligands. Curr Pharm Design 2002; 8(26): 2353-69.